# Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Source: https://onco.cc/trials/nct06056830/  
OnCo record `nct06056830` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, now recruiting.

## Summary

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy is a phase 3 interventional study registered as NCT06056830 by Clarity Pharmaceuticals Ltd, with 383 participants planned, started 2023-12-21 and due to reach its primary completion in 2026-09. Interventions recorded: 64Cu-SAR-bisPSMA.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06056830
- Phase: 3
- Setting: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study
- Sponsor: Clarity Pharmaceuticals Ltd
- Enrolled: 383

## Sources

- ClinicalTrials.gov NCT06056830: https://clinicaltrials.gov/study/NCT06056830

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Clarity Pharmaceuticals](https://onco.cc/companies/clarity-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06056830.json